AVITA Medical, Inc. (RCEL): Price and Financial Metrics


AVITA Medical, Inc. (RCEL): $5.69

0.18 (+3.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RCEL POWR Grades


  • RCEL scores best on the Value dimension, with a Value rank ahead of 48.12% of US stocks.
  • RCEL's strongest trending metric is Momentum; it's been moving down over the last 179 days.
  • RCEL ranks lowest in Momentum; there it ranks in the 16th percentile.

RCEL Stock Summary

  • AVITA Medical Inc's stock had its IPO on October 2, 2019, making it an older stock than merely 6.87% of US equities in our set.
  • The ratio of debt to operating expenses for AVITA Medical Inc is higher than it is for about merely 6.5% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.09 for AVITA Medical Inc; that's greater than it is for only 7.84% of US stocks.
  • If you're looking for stocks that are quantitatively similar to AVITA Medical Inc, a group of peers worth examining would be BNGO, CTSO, FLDM, AIRG, and AMST.
  • Visit RCEL's SEC page to see the company's official filings. To visit the company's web site, go to www.avitamedical.com.

RCEL Valuation Summary

  • RCEL's EV/EBIT ratio is -14.8; this is 150.51% lower than that of the median Healthcare stock.
  • RCEL's price/sales ratio has moved down 91.6 over the prior 23 months.
  • RCEL's price/earnings ratio has moved up 7.8 over the prior 23 months.

Below are key valuation metrics over time for RCEL.

Stock Date P/S P/B P/E EV/EBIT
RCEL 2021-08-31 16.1 4.4 -18.9 -14.8
RCEL 2021-08-30 16.0 4.3 -18.9 -14.7
RCEL 2021-08-27 16.3 4.4 -19.2 -15.1
RCEL 2021-08-26 14.5 3.9 -17.1 -12.9
RCEL 2021-08-25 23.0 3.8 -10.6 -8.0
RCEL 2021-08-24 23.1 3.8 -10.6 -8.0

RCEL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RCEL has a Quality Grade of D, ranking ahead of 9.85% of graded US stocks.
  • RCEL's asset turnover comes in at 0.314 -- ranking 128th of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows RCEL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.314 0.810 -5.438
2020-12-31 0.239 0.845 -0.901
2020-06-30 0.335 0.837 -3.514
2019-06-30 0.292 1.195 -1.429
2019-06-30 0.550 1.103 -1.428
2019-06-30 0.292 1.195 -1.429

RCEL Price Target

For more insight on analysts targets of RCEL, see our RCEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $40.60 Average Broker Recommendation 1.3 (Strong Buy)

RCEL Stock Price Chart Interactive Chart >

Price chart for RCEL

RCEL Price/Volume Stats

Current price $5.69 52-week high $22.49
Prev. close $5.51 52-week low $5.06
Day low $5.44 Volume 68,100
Day high $5.71 Avg. volume 142,111
50-day MA $6.91 Dividend yield N/A
200-day MA $12.22 Market Cap 142.00M

AVITA Medical, Inc. (RCEL) Company Bio


AVITA Medical, Inc. operates as a medicine company. The Company focuses on the development and commercialization of therapies to address unmet medical needs in patients with burns, chronic wounds, and aesthetics indications. AVITA Medical serves customers worldwide.


RCEL Latest News Stream


Event/Time News Detail
Loading, please wait...

RCEL Latest Social Stream


Loading social stream, please wait...

View Full RCEL Social Stream

Latest RCEL News From Around the Web

Below are the latest news stories about AVITA Medical Inc that investors may wish to consider to help them evaluate RCEL as an investment opportunity.

The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it has received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to market the RECELL® System in Japan. COSMOTEC, an M3 Group Company, championed the approval

Yahoo | February 23, 2022

AVITA Medical to Present at the Cowen 42nd Annual Health Care Conference

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that Dr. Mike Perry, CEO, will present at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 12:50 p.m. Eastern Standard Time (Wednesday, March 9, 2022 at 4:50 a.m.

Yahoo | February 23, 2022

AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use

System enhanced in response to clinician workflow and usability feedback; new system simplifies process United States product launch planned for Q2 2022 VALENCIA, Calif. and MELBOURNE, Australia, Feb. 17, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that the United States Food and Dr

Yahoo | February 17, 2022

AVITA Medical to Announce Transition Period July 1, 2021 to December 31, 2021 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it plans to release its July 1, 2021 to December 31, 2021 financial results after the market closes on Monday, February 28, 2022. In conjunction with such release, the Company plans

Yahoo | February 15, 2022

AVITA Medical to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

VALENCIA, Calif. and MELBOURNE, Australia, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that Dr. Mike Perry, CEO, will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 15, 2022 at 10:30 a.m. Eastern Standard Time (W

Yahoo | February 2, 2022

Read More 'RCEL' Stories Here

RCEL Price Returns

1-mo -9.83%
3-mo -36.99%
6-mo -59.04%
1-year -68.49%
3-year -82.27%
5-year -16.81%
YTD -52.50%
2021 -35.52%
2020 -59.16%
2019 712.50%
2018 4.67%
2017 -41.82%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7733 seconds.